Foresite Capital Management III’s Audentes Therapeutics, Inc BOLD Stock Holding History

Foresite Capital Management III’s Portfolio BOLD Stock Details BOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-233,067	Closed	-$13.9M	–	13
2019 Q4	$13.9M	Sell	233,067 -82,264	-26%	-$3.09M	7.82%	5
2019 Q3	$8.86M	Hold	315,331	–	–	3.38%	11
2019 Q2	$11.9M	Hold	315,331	–	–	3.92%	9
2019 Q1	$12.3M	Hold	315,331	–	–	3.2%	11
2018 Q4	$6.72M	Hold	315,331	–	–	2.21%	12
2018 Q3	$12.5M	Hold	315,331	–	–	2.75%	12
2018 Q2	$12M	Hold	315,331	–	–	2.59%	13
2018 Q1	$9.48M	Buy	+315,331	New	+$10.7M	2.07%	14
2017 Q2	–	Sell	-66,553	Closed	-$1.13M	–	34
2017 Q1	$1.13M	Hold	66,553	–	–	0.44%	23
2016 Q4	$1.22M	Hold	66,553	–	–	0.53%	17
2016 Q3	$1.19M	Buy	+66,553	New	+$1.01M	0.55%	14

Foresite Capital Management III's BOLD Position: Q1 2020 in Review

Foresite Capital Management III sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 233,067 shares — an estimated $13.9M sold.

Foresite Capital Management III first reported a position in BOLD in Q3 2016 and held it in 11 quarters. The position peaked at $13.9M in Q4 2019. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.

Foresite Capital Management III reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
Foresite Capital Management III sold 233,067 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $13.9M.
Foresite Capital Management III first reported a position in Audentes Therapeutics, Inc in Q3 2016 and held it in 11 quarters.
Foresite Capital Management III's Audentes Therapeutics, Inc position peaked at $13.9M in Q4 2019.
0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.

Based on Foresite Capital Management III's 13F filing for Q1 2020, filed 14 May 2020.